journal article·2020-01-01Open access

Enzyme/pH-triggered anticancer drug delivery of chondroitin sulfate modified doxorubicin nanocrystal

Yan Liang, Xiaoheng Fu, Chen Du, Haoran Xia, Yusi Lai, Yong Sun

Abstract

In this paper, we developed a novel strategy of preparing doxorubicin (DOX) nanocrystal (NC) exerting spherical particles with a diameter of 102 nm, which experienced following coating of chondroitin sulphate derivative (CSOA) shell via electrostatic and hydrophobic interactions. Such multifunctional outerwear resulted in drug nanocapsules with high drug loading content up to 70% and high colloidal stability under physiological conditions. It exhibited accelerated drug release behaviour when dispersing in hyaluronidase (HAase) containing medium or incubated with cancer cells. CSOA/NCs were effectively taken up by cancer cells via CD44 receptor-mediated endocytosis, but were rarely internalised into normal fibroblasts. With the comparison of typical drug-loaded micelles system (DOX/PEG-PCL), CSOA/NCs showed greater inhibition to cancer cells due to the targeted and sensitive drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Proteoglycans and glycosaminoglycans research · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmacy, Qingdao University

Department of Clinical laboratory, No.971 Hospital of the People’s Liberation Army Navy

Department of Marketing, Sichuan Kelun Pharmaceutical Co., Ltd

Funding

National Science Foundation of China · Shandong Provincial Natural Science Foundation

References (22)

Show source-provided references
1. 10.1016/j.biomaterials.2015.08.03210.1016/j.biomaterials.2015.08.032 ↗
2. 10.1038/nrd261410.1038/nrd2614 ↗
3. 10.1021/bc200667s10.1021/bc200667s ↗
4. 10.1039/b701327b10.1039/b701327b ↗
5. 10.1039/c2sm25683e10.1039/c2sm25683e ↗
6. 10.1021/nn201370710.1021/nn2013707 ↗
7. 10.1016/j.biomaterials.2016.05.02310.1016/j.biomaterials.2016.05.023 ↗
8. 10.1021/bc400326y10.1021/bc400326y ↗
9. 10.1039/c2cc33214k10.1039/c2cc33214k ↗
10. 10.1039/c1sm06053h10.1039/c1sm06053h ↗
11. 10.1016/j.biomaterials.2009.04.04110.1016/j.biomaterials.2009.04.041 ↗
12. 10.1021/ac000777a10.1021/ac000777a ↗
13. 10.1021/ja504118q10.1021/ja504118q ↗
14. Morelli D, Ménard S, Colnaghi MI, et al. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 1996;56(9):2082–2085.
15. 10.1021/ja064210910.1021/ja0642109 ↗
16. 10.1039/c3tb20392a10.1039/c3tb20392a ↗
17. 10.1039/C5BM00006H10.1039/C5BM00006H ↗
18. 10.1039/C4CC10226F10.1039/C4CC10226F ↗
19. 10.1016/j.biomaterials.2013.01.10110.1016/j.biomaterials.2013.01.101 ↗
20. 10.1021/acsami.6b1550510.1021/acsami.6b15505 ↗
21. 10.1021/acsami.7b1578010.1021/acsami.7b15780 ↗
22. 10.1002/adma.20130459210.1002/adma.201304592 ↗